Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
  • A23L33/12—Fatty acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
  • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7016—Disaccharides, e.g. lactose, lactulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/20—Milk; Whey; Colostrum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to preventing obesity by administering a nutritional composition to non-obese infants with the age below 3 years.
• the present invention relates to the treatment and/or prevention of type 2 diabetes.
• breast-feeding is the preferred method of feeding infants. However, there are circumstances that make breast-feeding impossible or less desirable. In those cases infant formulae are a good alternative. The composition of modern infant formulae is adapted in such a way that it meets many of the special nutritional requirements of the fast growing and developing infant.
• EP 1566439 pertains to a method for preventing and/or treating obesity.
• WO 2005/051091 relates to a substantially homogenous lipid preparation comprising a combination of glycerophospho lipids being phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinositol (PI), wherein the quantitative ratio between said glycerophospho lipids essentially mimics their corresponding ratio in naturally occurring human milk fat (HMF), optionally further comprising sphingomyelin (SM) and/or cholesterol, wherein the quantitative ratio between the glycerophospholipids in said combination and the sphingomyelin and/or cholesterol essentially mimics their corresponding ratio in said naturally occurring HMF.
• JP05292880 relates to buttermilk fat for inhibiting lipase activity.
• the present invention provides a composition wherein the lipid fraction is enriched in polar lipids, more particularly in glycerophospholipids, sphingolipids (especially sphingomyelin) and cholesterol. It was surprisingly found by the inventors that administration of a composition comprising glycerophospho lipids, sphingolipids (especially sphingomyelin) and cholesterol decreases insulin secretion when added to a nutritional composition, compared to the insulin secretion induced by the same nutritional formula without the present polar lipids.
• the present invention can therefore advantageously be used to prevent obesity later-in-life, but also to prevent the development of diabetes later in life.
• Inclusion of the present combination in infant nutrition reduces blood insulin levels and thereby the prevents the development of obesity and/or diabetes later in life. Since in infants high blood insulin levels particularly stimulate visceral adipocyte proliferation, the composition is particularly suitable to prevent visceral obesity.
• the present invention can also suitably be used for the manufacture of a nutritional composition for the prevention of type 2 diabetes, and/or for the dietary management of type 2 diabetes.
• the present invention provides the use of a composition comprising a lipid, protein and digestible carbohydrate component and (a) 0.5 to 20 wt.% phospholipids based on total lipid; (b) 0.1 to 20 wt.% sphingolipids based on total lipid; and (c) 0.005 to 10 wt.% cholesterol based on total lipid, for the manufacture of a nutritional composition to be administered to a (non-obese) infant with the age below 36 months for the prevention of obesity and/or type 2 diabetes.
• the present invention provides the use of a composition comprising a lipid, protein and digestible carbohydrate component and (a) 0.5 to 20 wt.% phospholipids based on total lipid; (b) 0.1 to 20 wt.% sphingolipids based on total lipid; and (c) 0.005 to 10 wt.% cholesterol based on total lipid for the manufacture of a nutritional composition to be administered to an infant with the age below 36 months for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea.
• the present invention provides the use of a composition comprising a lipid, protein and digestible carbohydrate component and: (a) 0.5 to 20 wt.% phospholipids based on total lipid; (b) 0.1 to 20 wt.% sphingo lipids based on total lipid; and (c) 0.005 to 10 wt.% cholesterol based on total lipid, for the manufacture of a nutritional composition for the prevention of type 2 diabetes and/or for the dietary management of type 2 diabetes.
• the present composition is preferably administered to a non-obese human infant with the age below 36 months, preferably below 18 months, more preferably below 12 months, even more preferably below 6 months.
• the present composition is administered to a non-overweight human with the age below 36 months, preferably below 18 months, more preferably below 12 months, even more preferably below 6 months of age.
• the absence or presence of obesity and/or overweight in an infant can suitably be determined by a physician.
• a non-obese infant below 36 months of age has gender specific weight-for-length below the 95 th percentile, more preferably below the 85 th percentile. Gender specific weight-for-length percentiles have been published by Center for Disease Control and Prevention (CDC) in 2000.
• Health related problems are especially associated with a special form of obesity, namely central obesity.
• the composition is used to prevent central obesity later-in-life.
• the term 'central obesity' refers to a condition with increased visceral fat mass.
• a waist circumference above 102 cm in adult man or above 88 cm in adult women indicates central obesity.
• For children of 3-19 years old appropriate cut-offs for age- and sex-dependent waist circumferences can be found in Taylor et al, 2000 Am J Clin Nutr 72:490-495.
• the present composition comprises a lipid component.
• the present composition comprises phospholipids, sphingolipids and cholesterol. Additionally the present composition preferably comprises triglycerides.
• the lipid component provides preferably 35 to 55% of the total calories. More preferably the present composition comprises a lipid component providing 40 to 50% of the total calories.
• the composition When in liquid form, e.g. as a ready-to-feed liquid, the composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g perl 00 ml. Based on dry weight the present composition preferably comprises 12.5 to 40 wt.% lipid, more preferably 19 to 30 wt.%.
• Phospholipids Phospholipids, sphingolipids and cholesterol
• oral administration of a composition comprising phospholipids, sphingolipids and cholesterol has the advantage that it decreases the post-prandial insulin response (see example 1), particularly when co-administered with a nutritional composition.
• the present composition comprises phospholipids.
• phospholipids as used in the present invention particularly refers to glycerophospholipids.
• Glycerophospholipids are normally a class of lipids formed from fatty acids esterified at the hydroxyl groups on carbon- 1 and carbon-2 of the backbone glycerol moiety and a negatively-charged phosphate group attached to carbon-3 of the glycerol via an ester bond, and optionally a choline group (in case of phosphatidylcholine), a serine group (in case of phosphatidylserine), an ethanolamine group (in case of phosphatidylethanolamine), an inositol group (in case of phosphatidylinositol) or a glycerol group (in case of phosphatidylglycerol) attached to the phosphate group.
• a choline group in case of phosphatidylcholine
• serine group in case of
• the present composition contains phosphatidylcholine (PC), phosphatidylserine, phosphatidylinositol and/or phosphatidylethanolamine, more preferably at least phosphatidylcholine.
• the present composition comprises sphingolipids.
• the term sphingo lipids as in the present invention particularly refers to glycolipids with an amino alcohol sphingosine.
• the sphingosine backbone is O-linked to a (usually) charged headgroup such as ethanolamine, serine or choline backbone.
• the backbone is also amide linked to a fatty acyl group.
• Sphingolipids include sphingomyelin, ceramides, and glycosphingolipids.
• the present composition contains sphingomyelin and/or glycosphingolipids.
• Glycosphingolipids are ceramides with one or more sugar residues joined in a ⁇ -glycosidic linkage at the 1-hydroxyl position.
• Glycosphingolipids may be further subdivided into cerebrosides, globosides and gangliosides. Cerebrosides have a single glucose or galactose at the 1 -hydroxy position, while gangliosides have at least three sugars, one of which must be sialic acid.
• Sphingomyelins have a phosphorylcholine or phosphoroethanolamine molecule esterified to the 1 -hydroxy group of a ceramide.
• the present composition contains gangliosides.
• the composition comprises sphingolipids, more preferably sphingomyelin and/or gangliosides, more preferably at least one ganglioside selected from the group consisting of GM3 and GD3.
• the present composition comprises cholesterol.
• the cholesterol is believed to further contribute to a reduced occurrence of obesity and/or type 2 diabetes.
• a further beneficial effect of dietary cholesterol is that it inhibits the endogenous cholesterol synthesis during infancy and programmes the endogenous cholesterol synthesis to lower levels. Consequently, reduced blood cholesterol levels later in life will be achieved. This results in a drop of LDL-cholesterol value in blood and a raise of HDL cholesterol value in blood during adolescence and adulthood.
• the present composition comprises 0.5 to 20 wt.% phospholipids based on total lipid, more preferably 1 to 10 wt.%, even more preferably 4 to 8 wt.%.
• the present composition comprises 0.1 to 20 wt.% sphingolipids based on total lipid, more preferably 0.5 to 10 wt.%, even more preferably 2 to 8 wt%.
• the present composition comprises 0.5 to 20 wt.% (sphingolipids plus phospholipids) based on total lipid, more preferably 1 to 10 wt.%, even more preferably 4 to 8 wt%.
• the present composition preferably comprises at least 0.005 wt.% cholesterol based on total fat, more preferably at least 0.01 wt.%, more preferably at least 0.05 wt.%., even more preferably at least 0.1 wt.%.
• the amount of cholesterol does not exceed 10 wt.% based on total lipid, more preferably does not exceed 5 wt.%, even more preferably does not exceed 1 wt.% of total lipid.
• Most preferably the amount of cholesterol is 0.5 to 0.7 wt.% based on total lipid.
• Preferred sources for providing the phospholipids, sphingolipids and cholesterol are egg lipids, milk fat, buttermilk fat and butter serum fat.
• a preferred source for phospholipids, particularly PC, is soy lecithin.
• the present composition preferably comprises soy lecithin, egg lipid, milk fat, butter serum fat and/or buttermilk fat, more preferably buttermilk fat.
• the present composition preferably comprises 0.05 to 10 grams buttermilk fat per 100 gram dry weight of the composition, preferably 0.1 to 3 gram. These amounts of buttermilk fat provide the blood insulin reducing effects.
• the buttermilk fat and butter serum fat is typically obtained from the manufacture of buttermilk and in particular from the whey that remains after manufacturing cheese from buttermilk.
• This milk whey comprises a relatively high amount of small fat globules, especially when macro molecules such as ⁇ -lactoglobulin have been removed.
• the concentration of small fat globules can be increased by applying filtration techniques on skimmed products, which concentrate the lipid layer on one side of the membrane and remove molecules like salts and lactose.
• Fractions that are enriched with acidic sphingoglyco lipids can also be isolated by applying chromatographic methods known in the art such as ion exchange.
• the buttermilk or butter serum fat contains at least 4 wt.% phospholipids per 100 gram lipid, more preferably 7 to 75 wt.%, most preferably 30 to 70 wt.% phospholipids per 100 gram lipid.
• the composition comprises digestible carbohydrate.
• the digestible carbohydrate component preferably provides 30 to 60% of the total calories.
• Preferably the present composition comprises a digestible carbohydrate component provides 40 to 50% of the total calories.
• Preferred digestible carbohydrate sources are lactose, glucose, sucrose, fructose, galactose, maltose, starch and maltodextrin.
• the maintenance of insulin sensitivity, while reducing blood insulin levels can improved by inclusion of a low glycaemic carbohydrate in the present composition, preferably lactose.
• the present composition preferably comprises lactose.
• the present composition preferably comprises a digestible carbohydrate component, wherein at least 35 wt.%, more preferably at least 50 wt.%, more preferably at least 75 wt.%, even more preferably at least 90 wt.%, most preferably at least 95 wt.% is lactose.
• the present composition preferably comprises at least 25 grams lactose per 100 gram dry weight of the present composition, preferably at least 40 grams lactose/100 gram.
• NDO non-digestible oligosaccharides
• the combination of phospholipids, sphingo lipids, cholesterol and non-digestible oligosaccharide is particularly effective in reducing blood insulin levels. It was surprisingly found that the combination of phospholipids, sphingo lip ids, cholesterol reduced the postprandial insulin secretion of non- digestible oligosaccharide containing nutritional compositions. This effect can be even further improved by including lactose as the (main) digestible carbohydrate source. The combination of phospholipids, sphingolipids, cholesterol and the non-digestible oligosaccharides synergistically reduces the obesity later in life
• the present composition comprises non-digestible oligosaccharides with a DP between 2 and 60.
• the composition preferably prevents the onset of insulin resistance.
• the non-digestible oligosaccharide is preferably selected from the group consisting of fructo- oligosaccharides (including inulin), galacto-oligosaccharides (including transgalacto- oligosaccharides), gluco-oligosaccharides (including gentio-, nigero- and cyclodextrin- oligosaccharides), arabino-oligosaccharides, mannan-oligosaccharides, xylo- oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno- oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligos
• the present composition comprises fructo- oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto-oligosaccharides.
• the composition comprises a mixture of transgalacto- oligosaccharides and fructo-oligosaccharides.
• the present composition comprises galacto-oligosaccharides with a DP of 2-10 and/or fructo-oligosaccharides with a DP of 2-60.
• the galacto-oligosaccharide is preferably selected from the group consisting of transgalacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT.
• the present method comprises the administration of transgalacto- oligosaccharides ([galactose] n -glucose; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, ...., 59 ,60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10).
• Transgalacto- oligosaccharides are for example sold under the trademark VivinalTM (Borculo Domo Ingredients, Netherlands).
• the saccharides of the transgalacto- oligosaccharides are ⁇ -linked.
• Fructo-oligosaccharide is a NDO comprising a chain of ⁇ linked fructose units with a DP or average DP of 2 to 250, more preferably 10 to 100.
• Fructo-oligosaccharide includes inulin, levan and/or a mixed type of polyfructan. An especially preferred fructo-oligosaccharide is inulin.
• Fructo-oligosaccharide suitable for use in the compositions is also already commercially available, e.g. Raftiline®HP (Orafti).
• Uronic acid oligosaccharides are preferably obtained from pectin degradation.
• the present composition preferably comprises a pectin degradation product with a DP between 2 and 100.
• the pectin degradation product is prepared from apple pectin, beet pectin and/or citrus pectin.
• the composition comprises transgalacto- oligosaccharide, fructo-oligosaccharide and a pectin degradation product.
• the weight ratio transgalacto-oligosaccharide : fructo-oligosaccharide : pectin degradation product is preferably 20 to2 : 1 : 1 to 3, more preferably 12 to 7 : 1 : 1 to 2.
• Fatty acyl chains are preferably 20 to2 : 1 : 1 to 3, more preferably 12 to 7 : 1 : 1 to 2.
• LA refers to linoleic acid (18:2 n6)
• ALA refers to ⁇ -linolenic acid (18:3 n3)
• LC- PUFA refers to long chain polyunsaturated fatty acids and/or acyl chains comprising at least 20 carbon atoms in the fatty acyl chain and with 2 or more unsaturated bonds
• DHA refers to docosahexaenoic acid (22:6, n3)
• EPA refers to eicosapentaenoic acid (20:5 n3)
• ARA refers to arachidonic acid (20:4 n6)
• DPA refers to docosapentaenoic acid (22:5 n3)
• DHGLA refers to dihomogammalinolenic acid (20:3 n6).
• Medium chain fatty acids (MCFA) refer to fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms. MCFA may also
• LA preferably is present in a sufficient amount in order to promote a healthy growth and development, yet in an amount as low as possible to prevent occurrence of obesity later in life.
• the composition therefore preferably comprises less than 15 wt.% LA based on total fatty acids, preferably between 5 and 14.5 wt.%, more preferably between 6 and 12 wt.%.
• ALA should be present in a sufficient amount to promote a healthy growth and development of the infant.
• the present composition therefore preferably comprises at least 1.0 wt.% based on total fatty acids.
• the composition comprises at least 1.6 wt.% ALA based on total fatty acids, more preferably at least 2.0 wt.%.
• the composition comprises less than 10 wt.% ALA, more preferably 5.0 wt.% based on total fatty acids.
• the weight ratio LA/ ALA should be well balanced in order to prevent obesity, especially central obesity, while at the same time ensuring a normal growth and development. Therefore, the present composition preferably comprises a weight ratio of LA/ALA between 2 and 15, more preferably between 2 and 7, more preferably between 3 and 6, even more preferably between 4 and 5.5, even more preferably between 4 and 5.
• the present composition preferably comprises at least 3 wt.% MCFA based on total fatty acids, more preferably at least 10 wt.%, even more preferably 15 wt.%. Since MCFA reduces body fat deposition with no preference for central fat mass, the present composition advantageously comprises less than 50 wt.% MCFA based on total fatty acids, more preferably less than 40 wt.%, even more preferably less than 25 wt.%.
• the present composition comprises LC-PUFA, since LC-PUFA reduce obesity later in life, more preferably central obesity. More preferably, the present composition comprises n-3 LC-PUFA, even more preferably EPA, DPA and/or DHA, even more preferably DHA. It was found that these n-3 LC-PUFA decrease obesity. Since a low concentration of DHA, DPA and/or EPA is already effective and normal growth and development are important, the content of n-3 LC-PUFA in the present composition, preferably does not exceed 15 wt.% of the total fatty acid content, preferably does not exceed 10 wt.%, even more preferably does not exceed 5 wt.%. Preferably the present composition comprises at least 0.2 wt.%, preferably at least 0.5 wt.%, more preferably at least 0.75 wt.%, n-3 LC-PUFA of the total fatty acid content.
• the present composition comprises relatively low amounts of AA.
• the n-6 LC- PUFA content preferably does not exceed 5 wt.%, more preferably does not exceed 0.8 wt.%, more preferably does not exceed 0.75 wt.%, even more preferably does not exceed 0.5 wt.%, based on total fatty acids.
• the amount of n-6 LC-PUFA is preferably at least 0.02 wt.% more preferably at least 0.05 wt.%, more preferably at least 0.1 wt.% based on total fatty acids, more preferably at least 0.25 wt.%.
• the presence of AA is advantageous in a composition low in LA since it remedies LA deficiency.
• the presence of, preferably low amounts, of AA is beneficial in nutrition to be administered to infants below the age of 6 months, since for these infants the infant formulae is generally the only source of nutrition.
• the weight ratio n-6 LC-PUFA / n-3 LC-PUFA in the present infant nutrition is preferably low in order to prevent obesity later in life.
• the composition comprises a weight ratio of n-6 LC-PUFA / n-3 LC-PUFA below 1.5, more preferably below 1.0, even more preferably below 0.6.
• the amount of saturated fatty acids is preferably below 58 wt.% based on total fatty acids, more preferably below 45 wt.%.
• the concentration of monounsaturated fatty acids preferably ranges from 17 to 60% based on weight of total fatty acids
• LA, ALA, MCFA and/or LC-PUFA are preferably provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, or as a mixture of one of more of the above.
• the present composition contains LC- PUFA in triglyceride and/or phospholipid form, even more preferably phospholipid form since LC-PUFA in phospholipid form are better incorporated into membranes.
• the present composition contains MCFA in triglyceride form.
• the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (including colza oil, low erucic acid rape seed oil and canola oil), salvia oil, perilla oil, purslane oil, lingonberry oil, sea buckthorn oil, hemp oil, high oleic sunflower oil, high oleic saffiower oil, olive oil, fish oil (especially tuna oil), single cell oil (including algal, microbial oil and fungal oil), black currant seed oil, echium oil, butter fat, coconut oil and palm kernel oil.
• linseed oil flaxseed oil
• rape seed oil including colza oil, low erucic acid rape seed oil and canola oil
• salvia oil perilla oil
• purslane oil lingonberry oil
• sea buckthorn oil hemp oil
• high oleic sunflower oil high oleic saffiower
• the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil, rapeseed oil, coconut oil, high oleic sunflower oil, butter oil, single cell oil and fish oil.
• lipid sources selected from the group consisting of linseed oil, rapeseed oil, coconut oil, high oleic sunflower oil, butter oil, single cell oil and fish oil.
• n-3 LC-PUFA single cell oil including algal oil and microbial oil, is used, since these oil sources have a low EPA/DHA ratio, which results in an increased anti-obesity effect.
• More preferably fish oil (even more preferably tuna oil) is used as a source of n-3 LC-PUFA since they have a higher EPA concentration which is advantageous since EPA is precursor of eicosanoids which have an additional anti-obesity effect.
• the present composition preferably comprises a source of uridine and/or choline.
• the composition comprises a source of uridine and choline.
• Choline is preferably added as choline chloride.
• the present composition preferably comprises choline chloride.
• the present composition preferably comprises at least 0.035 wt.% choline based on dry weight of the composition, more preferably at least 0.045 wt.%.
• the present composition comprises no more than 1 wt.% choline based on total dry weight of the present composition, more preferably below 0.5 wt.%, even more preferably below 0.1 wt.%.
• the presence of choline has the advantage that it is an excellent methyldonor.
• the composition of the present invention preferably comprises choline.
• the choline resulting from phospholipids is not calculated to contribute to this amount of methyl donor.
• the present composition comprises uridine in the form of a nucleotide, nucleoside and/or base.
• the present composition comprises uridine 5'-monophospate and/or salts thereof (collectively abbreviated to UMP), in particular monosodium salts thereof.
• the composition comprises 0.001 to 0.1 wt.% UMP based on dry weight of the present composition, more preferably 0.002 to 0.05 wt.%, most preferably 0.002 to 0.025 wt.%.
• UMP is preferably be added to the composition in a mixture of nucleotides.
• the present composition comprises proteins.
• the protein component preferably provides 5 to 15% of the total calories.
• Preferably the present composition comprises a protein component provides 6 to 12% of the total calories.
• the composition comprises vegetable protein and/or animal (non-human) milk protein.
• the composition comprises hydro lyzed casein and/or hydro lyzed whey protein. It was found that administration of a composition wherein the protein comprises hydro lyzed casein and/or hydro lyzed whey results in reduced post-prandial levels of both insulin and glucose compared to the administration of a composition comprising intact casein and intact whey protein.
• the present composition more preferably comprises more preferably casein hydrolysate and whey protein hydrolysate because the amino acid composition of bovine casein is more similar to the amino acid composition found in human milk protein and whey protein is easier to digest and found in greater ratios in human milk.
• the present composition is particularly suitable for providing the daily nutritional requirements to an infant with the age below 36 months, particularly an infant with the age below 24 months, even more preferably an infant with the age below 18 months, most preferably below 12 months of age.
• the present composition comprises a lipid, protein and digestible carbohydrate component wherein the lipid component preferably provides 35 to 55% of the total calories, the protein component preferably provides 5 to 15% of the total calories and the digestible carbohydrate component preferably provides 30 to 60% of the total calories.
• the present composition comprises a lipid component providing 40 to 50% of the total calories, a protein component provides 6 to 12% of the total calories and a digestible carbohydrate component provides 40 to 50% of the total calories.
• the present composition is not human breast milk.
• the present composition preferably comprises (i) vegetable lipid and/or animal (non-human) fat; and/or (ii) vegetable protein and/or animal (non-human) milk protein.
• the present composition preferably does not comprise a proteinase inhibitor, preferably not a trypsin inhibitor, chymotrypsin inhibitor or elastase inhibitor.
• the present composition is not human milk.
• the compositions of the inventions preferably comprise other fractions, such as vitamins, minerals according to international directives for infant formulae.
• Adipocytes including visceral adipocytes, proliferate during the first 36 months of life as well as (more limited) in puberty.
• the amount of adipocytes is an important determinant in the degree of obesity later-in-life.
• the present composition is preferably administered to the infant during the first 3 years of life. It was found that there is a predominance of proliferation of (visceral) adipocytes in the first 12 months of life (with an optimum in perinatal adipocyte proliferation). Hence, it is particularly preferred that the present composition is administered to the infant in this period of life.
• the present composition is therefore advantageously administered to a human of 0-24 months, more preferably to a human of 0-18 months, most preferably to a human of 0-12 months.
• the present invention particularly aims to prevent obesity later-in-life and is preferably not an obesity treatment.
• the present composition is preferably administered to an infant not suffering from obesity or childhood obesity, particularly a non-obese infant more preferably an infant that does not suffer from overweight.
• the present composition is preferably administered orally to the infant.
• the present invention also aims to prevent the occurrence of obesity and or diabetes at the age above 36 months, particularly to prevent obesity at the age above 8 years, particularly above 15 years, more particularly above 18 years.
• the composition is used to prevent obesity, more preferably central obesity, since especially central obesity is related to health disorders such as type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea, more preferably type 2 diabetes.
• health disorders such as type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea, more preferably type 2 diabetes.
• Example 1 Phospholipids beneficially affect insulin sensitivity
• Nutritional compositions A complete infant formula comprising lactose, galacto- oligosacharides with a DP 2-6 and fructo-oligosaccharides with DP 7-60 with extra added phospholipids (0.2 g/100 ml) was manufactured using a commercially available buttermilk/butter serum concentrate of Lactalis as source. An infant formula with a comparable composition, but without added phospholipids was used as control. The concentration of phospholipids was about 6.3 wt.% based on total lipid in the experimental formula and about 0.75 wt.% based on total lipid in the control formula. The experimental U
• composition comprised about 1.4 wt.% sphingomyelin based on total lipid and about 4 wt.% cholesterol based on total lipid.
• the amount of sphingomyelin and cholesterol was negligible in the control formula.
• Table 1 Effects of phospholipids on post-prandial area under the curve of insulin. Effect Standard Phospholipids Human milk
• Insulin (pM*15min) 14.8 ⁇ 2.1 13.8 ⁇ 1.6
• Intragastric injection of water or a cellulose solution in water on day 1 served as control.
• GOS fiber preparation consisted of 50% of digestible carbohydrates (mainly lactose), the two control injections were co-administered with carbohydrates to correct for this.
• Table 2 Insulin and glucose levels in rats.
• Infant nutrition comprising a lipid component providing 48% of the total calories, a protein component providing 8% of the total calories and a digestible carbohydrate component providing 44% of the total calories; (i) the lipid component comprising based on total fatty acids: 14 wt.% LA; 2.6 wt.% ALA, 3.7 wt.% MCFA; 0.2 wt.% DHA, 0.05 wt.% EPA; 0.02 wt.% DPA, 0.35 wt.% AA, 0.03 wt.% DHGLA.
• the composition comprises about 5.6 wt.% phospholipids, 1.4 wt.% sphingomyelin and about 4 wt.% cholesterol based on total lipid.
• the carbohydrate component comprising 50.9 gram lactose/100 gram powder, 5.22 g galacto-oligosaccharides with DP 2-6 and 0.58 g fructo-oligosaccharides with DP 7-60 per 100 g powder;
• the protein component comprising cow milk protein, including casein.
• the composition comprises 73 mg choline and 5.6 mg UMP per 100 g powder.
• the composition comprises vitamins and minerals according to EU guidelines. The label of the package of this infant nutrition indicates that the nutrition prevents the development of obesity.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nutrition Science (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Diabetes (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Mycology (AREA)
• Zoology (AREA)
• Immunology (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Virology (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Marine Sciences & Fisheries (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Developmental Biology & Embryology (AREA)
• Cardiology (AREA)
• Pediatric Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Urology & Nephrology (AREA)
• Neurology (AREA)

Priority Applications (9)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (2)

Family

ID=37964343

Family Applications (3)

Family Applications After (2)

Country Status (14)

Cited By (18)

Families Citing this family (57)

Family Cites Families (37)

• 2006
  • 2006-12-22 EP EP06824323A patent/EP1962617A2/en not_active Withdrawn
  • 2006-12-22 EP EP11150747A patent/EP2305049A1/en not_active Withdrawn
  • 2006-12-22 CA CA002634693A patent/CA2634693A1/en not_active Abandoned
  • 2006-12-22 MY MYPI20082246A patent/MY149164A/en unknown
  • 2006-12-22 AU AU2006327996A patent/AU2006327996B2/en active Active
  • 2006-12-22 EP EP06824324.5A patent/EP1973424B1/en active Active
  • 2006-12-22 CA CA002634895A patent/CA2634895A1/en not_active Abandoned
  • 2006-12-22 AU AU2006327995A patent/AU2006327995B2/en not_active Ceased
  • 2006-12-22 WO PCT/NL2006/050331 patent/WO2007073194A2/en not_active Ceased
  • 2006-12-22 RU RU2008130365/13A patent/RU2444210C2/ru not_active IP Right Cessation
  • 2006-12-22 US US12/158,931 patent/US20090186803A1/en not_active Abandoned
  • 2006-12-22 RU RU2008130367/15A patent/RU2414905C2/ru not_active IP Right Cessation
  • 2006-12-22 HU HUE06824326A patent/HUE026440T2/en unknown
  • 2006-12-22 PT PT68243260T patent/PT1962823E/pt unknown
  • 2006-12-22 WO PCT/NL2006/050329 patent/WO2007073193A2/en not_active Ceased
  • 2006-12-22 BR BRPI0620466-0A patent/BRPI0620466A2/pt not_active Application Discontinuation
  • 2006-12-22 WO PCT/NL2006/050328 patent/WO2007073192A2/en not_active Ceased
  • 2006-12-22 ES ES06824326.0T patent/ES2537080T3/es active Active
  • 2006-12-22 BR BRPI0620465-1A patent/BRPI0620465A2/pt not_active Application Discontinuation
  • 2006-12-22 US US12/158,857 patent/US20110136732A1/en not_active Abandoned
  • 2006-12-22 EP EP06824326.0A patent/EP1962823B1/en not_active Revoked
  • 2006-12-22 BR BRPI0620451-1A patent/BRPI0620451A2/pt not_active IP Right Cessation
  • 2006-12-22 CA CA002634117A patent/CA2634117A1/en not_active Abandoned
  • 2006-12-22 RU RU2008130370/13A patent/RU2417712C2/ru active
  • 2006-12-22 PL PL06824326T patent/PL1962823T3/pl unknown
  • 2006-12-22 JP JP2008547136A patent/JP2009521214A/ja active Pending
  • 2006-12-22 CN CN201310014398.XA patent/CN103054048B/zh active Active
  • 2006-12-22 AU AU2006327997A patent/AU2006327997B2/en active Active
  • 2006-12-23 MY MYPI20082287A patent/MY162091A/en unknown
• 2012
  • 2012-01-24 US US13/357,109 patent/US8871218B2/en active Active
• 2016
  • 2016-03-01 US US15/057,324 patent/US20160175393A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events